NVS logoNVS
Novartis AG

6,726
Loading...
Loading...
News
all
press releases
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zacks·23h ago
News Placeholder
More News
News Placeholder
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·2d ago
News Placeholder
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Zacks·3d ago
News Placeholder
Humana Extends TailorCare Tie-Up to Enhance MA Member Health
HUM expands its TailorCare partnership to Dallas and Denver, aiming to boost MA member health and cut MSK-related costs.
Zacks·10d ago
News Placeholder
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
Zacks·10d ago
News Placeholder
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
Zacks·15d ago
News Placeholder
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
Zacks·16d ago
News Placeholder
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·16d ago
News Placeholder
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Here is how Novartis (NVS) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks·17d ago
News Placeholder
INCY Announces New Late-Stage Data on Skin Disease Drug
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
Zacks·17d ago

Latest NVS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.